Takeda’s Plasma-derived Therapies Manufacturing Facility, Japan
Takeda will open a new plasma-derived therapy manufacturing facility by investing Y100bn ($755.8m) in Osaka by 2030.
Takeda Pharmaceutical Co Ltd
Pharmaceutical Products for the Biopharmaceutical Industry
Subscribed
You have successfully submitted your enquiry. Someone from our company will respond ASAP
About Us
Takeda is a biopharmaceutical company that carries out the research, development, production, and global commercialisation of pharmaceutical products. Its major business areas include gastroenterology (GI), rare diseases, plasma-derived therapies (PDT), oncology, and neurological disorders. Innovative biopharma is the largest component of Takeda’s R&D, and the company has produced new molecular entities (NMEs) that constitute potential medicines in areas with hitherto unmet medical needs. It manufactures medicines on four platforms, namely, biologics, gene, plasma, and cell. Some of its major products include Entyvio, Alofisel, Takhzyro, Livtencity, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Alunbrig, and Exkivity. The company also pursues growth opportunities in digital health companies through Takeda Digital Ventures.
Projects
Contact Details
Website
Email Address
Address
1-1, Nihonbashi-Honcho 2-chome,
Chuo-ku,
Tokyo,
103-8668,
Japan
Chuo-ku,
Tokyo,
103-8668,
Japan
Phone
Regional Offices
Address
Takeda Pharmaceutical Co Ltd
1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo
103-8668
Japan